Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 95 of 1,261
  1. US 12084502

    CD33-binding polypeptides and uses thereof

    Inhibrx Biosciences, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  2. US 12084481

    HV1 modulators and uses

    The Regents of the University of California · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  3. US 12084497

    SIRP1α targeted chimeric proteins and uses thereof

    Orionis Biosciences, Inc · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  4. US 12084514

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  5. US 12083224

    Lipid particles for nucleic acid delivery

    ARCTURUS THERAPEUTICS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  6. US 12084490

    Antibody based reagents that specifically recognize toxic oligomeric forms of tau

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  7. US 12084489

    Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  8. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Actinium Phamaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  9. US 12084350

    Allotrope of carbon having increased electron delocalization

    Structured Nano Carbon LLC · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  10. US 12084473

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  11. US 12083122

    Laureth-4 containing topical formulations

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  12. US 12083184

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  13. US 12084403

    Linkers for antibody drug conjugates

    The Board of Regents of the University of Texas System · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  14. US 12084515

    Compositions and methods for treatment of diabetic macular edema

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  15. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  16. US 12084670

    Regulating alkaloids

    22ND CENTURY LIMITED, LLC · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  17. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  18. US 12084468

    Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  19. US 12083118

    Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same

    ARBUTUS BIOPHARMA CORPORATION · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  20. US 12083246

    Composite gels and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  21. US 12084504

    Anti-MET antibodies and uses thereof

    AGOMAB THERAPEUTICS · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  22. US 12083191

    Composition and methods for imaging cells

    Northwestern University · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  23. US 12082565

    Non-human animals models of retinoschisis

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  24. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.